VANCOUVER, BC, March 27, 2023 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, ...
COMPASS Pathways' lead drug, COMP360, is a synthetic psilocybin in Phase 3 trials for TRD and Phase 2 for PTSD and AN. The company addresses unmet mental health needs through psychedelic therapies.
Compass Pathways’ journey to phase 3 psychedelic depression data is taking longer than expected. With the trials overrunning by months, the biotech is laying off 30% of its employees—including some ...
Understanding exactly how psychedelics promote new connections in the brain is critical to developing targeted, non-hallucinogenic therapeutics that can treat neurodegenerative and neuropsychiatric ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results